Company Description
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies.
Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers.
The company was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009.
The company was incorporated in 2005 and is headquartered in Calabasas, California.
| Country | United States |
| Founded | 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Amir Heshmatpour |
Contact Details
Address: 23975 Park Sorrento, Suite 205 Calabasas, California 91302 United States | |
| Phone | 310 663 7831 |
| Website | neonc.com |
Stock Details
| Ticker Symbol | NTHI |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001979414 |
| CUSIP Number | 64051A101 |
| ISIN Number | US64051A1016 |
| Employer ID | 92-1954864 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Amir Farrokh Heshmatpour | President, Chief Executive Officer, Executive Chairman and Secretary |
| Dr. Thomas C. Chen M.D., Ph.D. | Founder, Chief Medical Officer, Chief Scientific Officer and Vice Chairman |
| Keithly A. Garnett | Chief Financial Officer |
| Dr. Josh Neman-Ebrahim Ph.D. | Chief Clinical Officer |
| David Choi Jr. | Chief Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 24, 2026 | 8-K | Current Report |
| Apr 16, 2026 | EFFECT | Notice of Effectiveness |
| Apr 16, 2026 | 8-K | Current Report |
| Apr 16, 2026 | 424B5 | Filing |
| Apr 10, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Apr 10, 2026 | 8-K | Current Report |
| Apr 10, 2026 | 424B5 | Filing |
| Apr 9, 2026 | EFFECT | Notice of Effectiveness |
| Apr 3, 2026 | 8-K | Current Report |
| Apr 2, 2026 | S-3 | Registration statement under Securities Act of 1933 |